Press release
Adrenoleukodystrophy Pipeline Outlook, Clinical Trials, FDA Approvals, and Companies 2024 (Updated)
Adrenoleukodystrophy Pipeline
Key Takeaways from the Adrenoleukodystrophy Pipeline Report
• DelveInsight's Adrenoleukodystrophy pipeline report depicts a robust space with 8+ active players working to develop 8+ pipeline therapies for Adrenoleukodystrophy treatment.
• The leading companies working in the Adrenoleukodystrophy Market include Bluebird bio, Applied Genetic Technologies Corporation, Poxel, Minoryx Therapeutics, Orpheris, MedDay Pharmaceuticals, Viking Therapeutics, and others.
• Promising Adrenoleukodystrophy Pipeline Therapies in the various stages of development include Leriglitazone, MIN-102, VK0214, MD1003 100 mg capsule, SBT101, Cholic Acids, OP-101, and others.
• April 2024:- BlueBird Bio- A Postmarketing, Prospective, Multicenter, Observational, Long-Term Safety and Effectiveness Registry Study of Patients With Cerebral Adrenoleukodystrophy (CALD) Treated With Elivaldogene Autotemcel (Stargazer). The main aim of this study is to assess and describe the safety outcomes, including newly diagnosed malignancies, of patients with CALD treated with eli-cel in the post-marketing setting (tradename Skysona) and to describe major functional disability (MFD)-free survival over time in participants with more advanced early active CALD. All enrolled participants with CALD treated with eli-cel in the post-marketing setting will be followed in this study for 15 years.
• March 2024:- Minoryx Therapeutics, S.L.- A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy. A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adults Male Subjects with Cerebral Adrenoleukodystrophy.
Request a sample and discover the recent advances in Adrenoleukodystrophy Treatment Drugs @ Adrenoleukodystrophy Pipeline Report- https://www.delveinsight.com/report-store/adrenoleukodystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
In the Adrenoleukodystrophy pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Adrenoleukodystrophy NDA approvals (if any), and product development activities comprising the technology, Adrenoleukodystrophy (ALD) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Adrenoleukodystrophy Overview
Adrenoleukodystrophy (ALD) is a rare, X-linked metabolic disorder. ALD is caused by mutations in the ABCD1 gene that affect the production of adrenoleukodystrophy protein (ALDP) and subsequently cause toxic accumulation of very long-chain fatty acids (VLCFAs) primarily in the adrenal cortex and white matter of the brain and spinal cord.
Find out more about Adrenoleukodystrophy Therapeutics Assessment @ Adrenoleukodystrophy Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/adrenoleukodystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Adrenoleukodystrophy Emerging Drugs Profile
• Elivaldogene autotemcel: bluebird bio
• Leriglitazone: Minoryx Therapeutics
Adrenoleukodystrophy Pipeline Therapeutics Assessment
There are approx. 8+ key companies which are developing the Adrenoleukodystrophy therapies. The Adrenoleukodystrophy companies which have their Adrenoleukodystrophy (ALD) drug candidates in the most advanced stage, i.e. Phase III include, bluebird bio.
DelveInsight's Adrenoleukodystrophy pipeline report covers around 8+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Adrenoleukodystrophy Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
• Molecule Type
Adrenoleukodystrophy Pipeline Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type
Learn more about the emerging Adrenoleukodystrophy Pipeline Therapies @ Adrenoleukodystrophy Clinical Trials Assessment- https://www.delveinsight.com/sample-request/adrenoleukodystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Adrenoleukodystrophy Pipeline Report
• Coverage- Global
• Adrenoleukodystrophy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Adrenoleukodystrophy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Adrenoleukodystrophy Companies- Bluebird bio, Applied Genetic Technologies Corporation, Poxel, Minoryx Therapeutics, Orpheris, MedDay Pharmaceuticals, Viking Therapeutics, and others.
• Adrenoleukodystrophy Pipeline Therapies- Leriglitazone, MIN-102, VK0214, MD1003 100 mg capsule, SBT101, Cholic Acids, OP-101, and others.
Dive deep into rich insights for new drugs for Adrenoleukodystrophy Treatment, Visit @ Adrenoleukodystrophy Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/adrenoleukodystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Adrenoleukodystrophy Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Adrenoleukodystrophy (ALD) - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Adrenoleukodystrophy (ALD) Collaboration Deals
9. Late Stage Products (Preregistration)
10. Elivaldogene autotemcel: bluebird bio
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II/III)
13. Leriglitazone: Minoryx Therapeutics
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. OP 101: Orpheris
17. Drug profiles in the detailed report…..
18. Preclinical/Discovery Stage Products
19. Research programme: Adrenoleukodystrophy gene therapy: AGTC
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Adrenoleukodystrophy Companies
23. Adrenoleukodystrophy Products
24. Adrenoleukodystrophy Unmet Needs
25. Adrenoleukodystrophy Market Drivers and Barriers
26. Adrenoleukodystrophy Future Perspectives and Conclusion
27. Adrenoleukodystrophy Analyst Views
28. Adrenoleukodystrophy Companies
29. Appendix
For further information on the Adrenoleukodystrophy Pipeline therapeutics, reach out to Adrenoleukodystrophy Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/adrenoleukodystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
List of Important Links-
http://demo.advised360.com/read-blog/154799
https://thehealthbridges.com/read-blog/19127
https://app.talkshoe.com/user/joneswilliam/about#google_vignette
https://www.vaca-ps.org/blogs/142022/The-Evolving-Landscape-of-Healthcare-Business-Consulting-Services
https://www.anobii.com/en/01d38d0b9694756e64/profile/activity
https://myanimelist.net/profile/dennydonesgerman
https://forum.pivx.org/threads/healthcare-business-consulting-services-navigating-complexity-in-modern-healthcare.2035/
https://pubhtml5.com/homepage/npvs/
https://b31.org.uk/author/anniesmith9/
https://fairygodboss.com/users/profile/Ix-vMa09gj/Annie-Smith
https://forum.completefrance.com/index.php?/topic/71194-key-areas-of-focus-in-healthcare-consulting-services/
https://educatorpages.com/site/kelleadvin/pages/blog?
https://offgridworld.com/author/anniejones9/
https://www.openhumans.org/member/me/
https://findpenguins.com/5zphebtv0zouo
http://jobs.emiogp.com/author/williamsmith9/
https://www.shippingexplorer.net/en/user/williamsmith9/88249
https://wakelet.com/@DennyDones813
https://startupxplore.com/en/person/denny-dones
https://www.nfpjobs.com.au/employers/1939365-delveinsight
https://community.hodinkee.com/members/dennydoness
https://jobs.mikeroweworks.org/employers/1930150-delveinsight
https://www.social-vape.com/read-blog/132516
https://codex.core77.com/users/dennydones9
https://www.newjerseyhunter.com/members/dennydones1.84566/#about
https://au.blurb.com/user/dennydones9?profile_preview=true
https://trabajo.merca20.com/author/kelleadvin/
https://www.atlasobscura.com/users/dennydones1
https://www.mixcloud.com/dennydones1/
https://www.designspiration.com/ybhardwaj/
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:- https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Adrenoleukodystrophy Pipeline Outlook, Clinical Trials, FDA Approvals, and Companies 2024 (Updated) here
News-ID: 3471778 • Views: …
More Releases from DelveInsight Business Research LLP
Optic Neuritis Therapeutics Market Size in the 7MM was ~USD 3 Million in 2024 an …
DelveInsight's "Optic Neuritis Market Insight, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of Optic Neuritis, historical and forecasted epidemiology as well as the Optic Neuritis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Unlock detailed insights into the Optic Neuritis Market by downloading the comprehensive report from DelveInsight @ https://www.delveinsight.com/sample-request/optic-neuritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash
Key Takeaways from the Optic Neuritis…
Stargardt Disease Therapeutics Market Size in the 7MM is anticipated to increase …
DelveInsight's "Stargardt Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Stargardt Disease, historical and forecasted epidemiology as well as the Stargardt Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Discover Key Insights into the Stargardt Disease Market with DelveInsight's In-Depth Report @ https://www.delveinsight.com/sample-request/stargardt-disease-stgd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash
Key Takeaways from the Stargardt Disease Market Report
• In August 2026, Belite…
Surgical Site Infections Therapeutics Market Size in the 7MM is anticipated to i …
DelveInsight's "Surgical Site Infections Market Insights, Epidemiology, and Market Forecast-2036′′ report offers an in-depth understanding of the Surgical Site Infections, historical and forecasted epidemiology as well as the Surgical Site Infections market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
Discover Key Insights into the Surgical Site Infections Market with DelveInsight's In-Depth Report @ https://www.delveinsight.com/sample-request/surgical-site-infections-ssi-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash
Key Takeaways from the Surgical Site Infections Market Report
• In…
Nontuberculous Mycobacteria Infections Treatment Market Size was more than USD 7 …
DelveInsight's "Nontuberculous Mycobacterial Infections Market Insights, Epidemiology, and Market Forecast-2036" report delivers an in-depth understanding of NTM Infections, historical and forecasted epidemiology, as well as the NTM Infections market trends in the United States.
Explore the intricate details of the Nontuberculous Mycobacterial Infections Market @ https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-ntm-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash
Key Takeaways from the Non-Tuberculous Mycobacterial Infections Market Report
• In August 2026, MicuRx Pharmaceuticals received FDA clearance for the IND application for MRX-5, enabling the company…
More Releases for Adrenoleukodystrophy
Adrenoleukodystrophy (ALD) Market Opportunities in 2034
Market Overview
The Adrenoleukodystrophy (ALD) Market is growing steadily as improvements in newborn screening, genetic diagnostics, and awareness of rare neurodegenerative disorders lead to earlier detection and clinical intervention.
ALD is a genetically inherited X-linked disorder caused by mutations in the ABCD1 gene, leading to the toxic accumulation of very long-chain fatty acids (VLCFAs) in the brain, adrenal glands, and spinal cord. The condition manifests in multiple forms, including childhood cerebral…
Adrenoleukodystrophy Treatment Market: Transforming Rare Disease Therapeutics
The adrenoleukodystrophy treatment market was valued at approximately USD 1.1 billion in 2023 and is anticipated to reach around USD 2.4 billion by 2033, growing at a CAGR of 8.1% from 2024 to 2033.
The adrenoleukodystrophy (ALD) treatment market represents a critical segment within the rare disease therapeutics landscape, addressing one of the most challenging genetic disorders affecting the nervous system and adrenal glands. This X-linked genetic condition, caused by mutations…
X-linked Adrenoleukodystrophy Pipeline Therapeutics Assessment Report 2024 (Upda …
DelveInsight's, "X-Linked Adrenoleukodystrophy Pipeline Insight, 2024," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in X-Linked Adrenoleukodystrophy (X-ALD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in X-linked adrenoleukodystrophy Research. Learn more…
Adrenoleukodystrophy Pipeline, FDA Approvals, Clinical Trials Developments and C …
DelveInsight's, "Adrenoleukodystrophy Pipeline Insight, 2023," report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in the Adrenoleukodystrophy pipeline landscape. It covers the Adrenoleukodystrophy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Adrenoleukodystrophy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Adrenoleukodystrophy Pipeline Report
• DelveInsight's Adrenoleukodystrophy…
Adrenoleukodystrophy Market Size, Market Trends & Analysis till 2033
Market Overview:
The adrenoleukodystrophy market is expected to exhibit a CAGR of 1.84% during 2023-2033. The adrenoleukodystrophy market report offers a comprehensive analysis of the market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs available in the market, drugs in development, the market share of various therapies, and the market's performance in the seven major…
Adrenoleukodystrophy (ADL) – Competitive Landscape, Epidemiology Forecast, and …
Adrenoleukodystrophy (ADL) is defined as a X-linked disorder which is more prominent in males. This disorder affects the adrenal glands. In this disease the fatty covering over the neurons and spinal cord starts deteriorating, thus reducing nerve’s ability to transfer the information. The damage to adrenal glands leads to reduction in the level of adrenocortical hormones.
Download the sample report at: https://www.pharmaproff.com/request-sample/1156
This reduced level in turn causes weakness, weight loss,…
